Dr. Kelly earned his Ph.D. in Biochemistry from the University of Washington in the laboratory of Dr. Richard Palmiter, developing transgenic and knockout mouse models to study the function of the metal-binding protein metallothionein. Following a post-doctoral fellowship in molecular toxicology at the Department of Environmental Health with Dave Eaton, he ventured into Biotech, managing the Preclinical Bioanalytics group at Targeted Genetics Corporation, evaluating the safety and efficacy of gene therapies for diseases such as cystic fibrosis, rheumatoid arthritis and hemophilias. Upon his return to academia, his research interests have stayed within the realm of preclinical biology. His lab works on developing novel models to study normal human physiology and disease states, with a particular focus on cytochrome P450 enzymes and their role in endobiotic/xenobiotic metabolism. Specific areas include studying the heritable ocular disease, Bietti’s Crystalline Dystrophy, derivation of metabolically active hepatocytes from embryonic stem cells and development of a human kidney “organ-on-a-chip”.